Sign in
HOWL Stock Price, Chart, Stats & News
Werewolf Therapeutics, Inc.
Save
17.81M
Market cap
–
Current P/E
–
Forward P/E
HOWL chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -87.64% |
ROE | -158.81% |
D/E | 0.38x |
Interest coverage ratio | -13.26x |
HOWL valuation
P/E | – |
P/S | – |
P/B | 1.45x |
P/CF | -0.60x |
P/FCF | -0.63x |
P/OCF | -0.60x |
PEG | -0.03x |
EV multiple | -1.46x |
About
Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments.
Similar securities
Based on sector and market capitalization
Report issue